Pfizer Adds Payoff to Pipeline Drugs in Deal at $22 Billion

Pfizer Adds Payoff to Pipeline Drugs in Deal at $22 Billion

Andrew Harrer/Bloomberg

Divesting the units which generate $5.5 billion in annual sales, or 8 percent of the New York-based company’s revenue also lets Pfizer sharpen its focus on developing the three drugs.